Accelerate Diagnostics Inc (AXDX)vsAstraZeneca PLC (AZN)
AXDX
Accelerate Diagnostics Inc
$0.03
0.00%
HEALTHCARE · Cap: $859,920
AZN
AstraZeneca PLC
$160.17
+0.33%
HEALTHCARE · Cap: $252.33B
Smart Verdict
WallStSmart Research — data-driven comparison
AstraZeneca PLC generates 524485% more annual revenue ($61.37B vs $11.70M). AZN leads profitability with a 17.0% profit margin vs 0.0%. AZN earns a higher WallStSmart Score of 60/100 (C+).
AXDX
Avoid25
out of 100
Grade: F
AZN
Buy60
out of 100
Grade: C+
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Intrinsic value data unavailable for AXDX.
Margin of Safety
+18.4%
Fair Value
$196.10
Current Price
$160.17
$35.93 discount
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
No standout strengths identified
Mega-cap, among the largest globally
Every $100 of equity generates 21 in profit
Strong operational efficiency at 23.5%
Generating 2.1B in free cash flow
Areas to Watch
0.0% earnings growth
Smaller company, higher risk/reward
ROE of 0.0% — below average capital efficiency
0.0% margin — thin
2.5% earnings growth
Distress zone — elevated risk
Comparative Analysis Report
WallStSmart ResearchBull Case : AXDX
AXDX has a balanced fundamental profile.
Bull Case : AZN
The strongest argument for AZN centers on Market Cap, Return on Equity, Operating Margin. Profitability is solid with margins at 17.0% and operating margin at 23.5%. PEG of 1.28 suggests the stock is reasonably priced for its growth.
Bear Case : AXDX
The primary concerns for AXDX are EPS Growth, Market Cap, Return on Equity.
Bear Case : AZN
The primary concerns for AZN are EPS Growth, Altman Z-Score.
Key Dynamics to Monitor
AXDX profiles as a value stock while AZN is a mature play — different risk/reward profiles.
AXDX carries more volatility with a beta of 0.22 — expect wider price swings.
AZN is growing revenue faster at 6.4% — sustainability is the question.
AZN generates stronger free cash flow (2.1B), providing more financial flexibility.
Bottom Line
AZN scores higher overall (60/100 vs 25/100), backed by strong 17.0% margins. Both earn "Buy" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Accelerate Diagnostics Inc
HEALTHCARE · MEDICAL DEVICES · USA
Accelerate Diagnostics, Inc., an in vitro diagnostic company, offers solutions for diagnosing serious infections in the United States, Europe, and the Middle East. The company is headquartered in Tucson, Arizona.
AstraZeneca PLC
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
AstraZeneca PLC discovers, develops, manufactures and markets prescription drugs in the areas of oncology, cardiovascular, renal and metabolism, respiratory, infections, neuroscience and gastroenterology worldwide. The company is headquartered in Cambridge, the United Kingdom.
Compare with Other MEDICAL DEVICES Stocks
Want to dig deeper into these stocks?